Nordic Nanovector announces that a poster describing the therapeutic effect of combined treatment with Betalutin and rituximab in a preclinical model of non-Hodgkin lymphoma will be presented at the 58th Annual American Society of Hematology meeting.
Nordic Nanovector ASA (OSE:NANO)(OSE:NANOO) announces that a poster describing the therapeutic effect of combined treatment with Betalutin® (177Lu-satetraxetan-lilotomab) and rituximab in a preclinical model of
non-Hodgkin lymphoma (NHL) (abstract 4189) will be presented at the 58th Annual American Society of Hematology (ASH) meeting (3-6 December 2016 in San Diego, CA, USA). These studies build on previously presented data showing that treatment with Betalutin® increased binding of rituximab to NHL cells and uptake of rituximab in NHL tumours. The combination treatment resulted in 90-100 % survival for 150 days after treatment,
while each treatment alone gave from 10 to 40 % survival.
The ASH annual meeting is the premier event for scientific exchange in
the field of hematology, attracting more than 20,000 attendees from all
over the world. Typically, more than 5,000 scientific abstracts are
submitted each year, and more than 3,000 abstracts are accepted for oral
and poster presentations through an extensive peer review process.
Abstract title: Combination of 177lutetium-Satetraxetan-Lilotomab and
Rituximab Results in Improved Therapeutic Effect in Preclinical Models
of Non-Hodgkin Lymphoma
Authors: Repetto-Llamazares, AHV et al.
Session Name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic
Agents: Poster III
Date/Time: Monday, 5 December 2016, 6:00 PM – 8:00 PM (PST)
Location: San Diego Convention Center, Hall GH
Link to abstract: https://ash.confex.com/ash/2016/webprogram/Paper89561.html
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates
(ARC) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab
(previously referred to as HH1), conjugated to a low intensity
radionuclide (lutetium-177). The preliminary data has shown promising
efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at
developing Betalutin® for the treatment of major types of NHL with first
regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com